1181120

Alnylam Pharmaceuticals, Inc. — FEI 3004080452

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
September 9, 2022
Fiscal Year
2022
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Cambridge, MA (United States)

Additional Details

Postmarket Adverse Drug Experience (PADE)